Literature DB >> 11589673

Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients.

G Minniti1, C Moroni, M L Jaffrain-Rea, V Esposito, A Santoro, C Affricano, G Cantore, G Tamburrano, R Cassone.   

Abstract

OBJECTIVE: Transsphenoidal surgery results in biochemical remission of acromegaly in 45-80% of patients; however, few studies have addressed the impact of transsphenoidal surgery on cardiovascular function in acromegalic patients. The aim of this prospective study was to investigate the effects of postoperative GH/IGF-I normalization on echocardiographic parameters and blood pressure (BP) in a series of patients with active acromegaly.
DESIGN: An open prospective study. PATIENTS: Thirty newly diagnosed acromegalic patients undergoing transsphenoidal surgery. MEASUREMENTS: Doppler echocardiography and 24-h ambulatory blood pressure monitoring were performed before and 6 months after transsphenoidal surgery.
RESULTS: Fifteen patients were considered to be well controlled postoperatively (group A), as defined by normal age-corrected IGF-I levels and glucose-suppressed GH levels less than 2 mU/l, the remaining 15 patients being considered as poorly controlled (group B). In group A, a postoperative decrease of left ventricular mass index was observed (104.4 +/- 6.6 vs. 127.1 +/- 7.7 g/m2; P < 0.001), associated with an improvement of some indices of diastolic function, such as an increase of the early/late transmitral peak flow velocity (P < 0.05) and a decrease of isovolumic relaxation time (P < 0.01). No significant change was observed in group B. A significant decrease of 24-h systolic BP was also observed in group A (P < 0.05) and five of six patients normalized their BP circadian rythm. In contrast, a nonsignificant increase in BP values, with a persistent blunted BP profile where present, was observed in group B.
CONCLUSIONS: We conclude that successful transsphenoidal surgery is able to induce a significant improvement in some cardiac parameters and a slight reduction in systolic blood pressure in acromegalic patients.

Entities:  

Mesh:

Year:  2001        PMID: 11589673     DOI: 10.1046/j.1365-2265.2001.01343.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  18 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

Review 2.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

Review 3.  The cardiovascular system in growth hormone excess and growth hormone deficiency.

Authors:  G Lombardi; C Di Somma; L F S Grasso; M C Savanelli; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

Review 4.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

5.  Is left ventricular dysfunction reversed after treatment of active acromegaly?

Authors:  Savvas T H Toumanidis; Maria Eleftheria Evangelopoulos; Ioannis Ilias; Constantinos Pamboucas; Chrysanthi Trikka; Maria Alevizaki
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 6.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

7.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 8.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  Surgical treatment of pituitary tumors in the elderly: clinical outcome and long-term follow-up.

Authors:  Luigi Ferrante; Giuseppe Trillò; Epimenio Ramundo; Paolo Celli; Marie-Lise Jaffrain-Rea; Maurizio Salvati; Vincenzo Esposito; Raffaele Roperto; Mattia Falchetto Osti; Giuseppe Minniti
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

Review 10.  Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.

Authors:  Matteo Parolin; Francesca Dassie; Chiara Martini; Roberto Mioni; Lucia Russo; Francesco Fallo; Marco Rossato; Roberto Vettor; Pietro Maffei; Claudio Pagano
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.